Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

Alignment reached on key elements of ATH434 Phase 3 development programMELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ...

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2025, and ...

ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...
American Council on Science and Health

The Evolution of Post-Fentanyl Drugs Mirrors That of Microbial Drug Resistance

Drug policy and microbiology might seem like completely different worlds. But both are shaped by the same evolutionary ...

Atossa Therapeutics Inc: Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel ...
TCTMD

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

The results run counter to ABYSS but align with other data showing beta-blockers shouldn’t continue indefinitely after MI.